IN THE CLAIMS

1. (Original) A use of N-acetyl-D-glucosamine or pharmaceutically acceptable salts thereof in treating and controlling local lesions and systematic symptoms caused by autoimmune reactions.

2 (Original) A use of N-acetyl-D-glucosamine or pharmaceutically acceptable salts thereof in the manufacture of a medicament for treating and controlling local lesions and systematic symptoms caused by autoimmune reactions.

3. (Original) A use according to claim 2, wherein said medicament is a preparation suitable for intravenous injection, subcutaneous injection, intramuscular injection, intra-peritoneal injection, or oral administration.

4. (Currently amended) A use according to claim 2 [[or 3]], wherein the dose of said medicament for an adult patient is 1-100000 mg per day based on the active component, and said medicament is administered one to four times daily.

5. (New) A use according to claim 3, wherein the dose of said medicament for an adult patient is 1-100000 mg per day based on the active component, and said medicament is administered one to four times daily.

6. [[5]] (Currently amended) A method for treating and controlling local lesions and systematic symptoms caused by autoimmune reactions, wherein a pharmaceutical composition comprising an effective amount of N-acetyl-D-glucosamine or pharmaceutically acceptable salts thereof is administered to a patient.

7. [[6]] (Currently amended) A method according to claim [[5]] 6, wherein said pharmaceutical composition is a preparation suitable for intravenous injection, subcutaneous injection, intramuscular injection, intra-peritoneal injection, or oral administration.

8. [[7]] (Currently amended) A method according to claim [[5 or]] 6, wherein the dose of said pharmaceutical composition for an adult patient is 1-100000 mg per day based on the active component.

9. (New) A method according to claim 7, wherein the dose of said pharmaceutical composition for an adult patient is 1-100000 mg per day based on the active component.